NASDAQ:PRTG Portage Biotech (PRTG) Stock Forecast, Price & News $2.55 -0.06 (-2.30%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$2.49▼$2.5950-Day Range$2.35▼$3.4552-Week Range$2.30▼$8.03Volume11,017 shsAverage Volume23,712 shsMarket Capitalization$45.39 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Portage Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside396.7% Upside$12.67 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector221st out of 965 stocksCrude Petroleum & Natural Gas Industry45th out of 78 stocks 3.5 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.67, Portage Biotech has a forecasted upside of 396.7% from its current price of $2.55.Amount of Analyst CoveragePortage Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 27.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 3.2 News and Social Media Coverage News SentimentPortage Biotech has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Portage Biotech this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Portage Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.00% of the stock of Portage Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Portage Biotech (NASDAQ:PRTG) StockPortage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.Read More PRTG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTG Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceSeptember 7, 2023 | markets.businessinsider.comAnalyst Expectations for Portage Biotech's FutureSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 5, 2023 | marketwatch.comPortage Biotech in Keytruda Collaboration With MerckSeptember 5, 2023 | finance.yahoo.comPortage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid TumorsSeptember 1, 2023 | msn.comCantor Fitzgerald Reiterates Portage Biotech (PRTG) Overweight RecommendationAugust 30, 2023 | finance.yahoo.comPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business UpdateAugust 2, 2023 | msn.comHC Wainwright & Co. Maintains Portage Biotech (PRTG) Buy RecommendationSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 2, 2023 | markets.businessinsider.comPortage Biotech Inc (PRTG) Receives a Buy from H.C. WainwrightAugust 2, 2023 | health.usnews.comUniversity Hospitals Portage Medical CenterAugust 1, 2023 | msn.comCantor Fitzgerald Maintains Portage Biotech (PRTG) Overweight RecommendationJuly 31, 2023 | finance.yahoo.comPortage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business UpdateJune 26, 2023 | finance.yahoo.comPortage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid TumorsJune 5, 2023 | benzinga.comWhy Portage Biotech Stock Is Up TodayJune 5, 2023 | finance.yahoo.comPortage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual MeetingJune 1, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion During the 2023 BIO International ConferenceApril 29, 2023 | usnews.comPortage Central High SchoolApril 26, 2023 | finance.yahoo.comPortage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 19, 2023 | usnews.comPortage High SchoolApril 12, 2023 | nytimes.comTrack Covid-19 in Portage County, WisconsinMarch 12, 2023 | benzinga.comPortage Biotech Stock (NASDAQ:PRTG), DividendsMarch 7, 2023 | finance.yahoo.comPortage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comPortage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022February 27, 2023 | finance.yahoo.comPortage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in CancerFebruary 23, 2023 | msn.comPortage Biotech reports FY resultsFebruary 15, 2023 | finance.yahoo.comPortage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership SummitSee More Headlines Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTG Company Calendar Last Earnings8/30/2023Today9/22/2023Next Earnings (Estimated)12/05/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Crude petroleum & natural gas Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.67 High Stock Price Forecast$18.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+396.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.07% Return on Assets-69.67% Debt Debt-to-Equity RatioN/A Current Ratio4.13 Quick Ratio4.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.45 per share Price / Book0.57Miscellaneous Outstanding Shares17,800,000Free Float10,312,000Market Cap$45.39 million OptionableNot Optionable Beta1.31 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ian B. Walters M.B.A. (Age 55)M.D., CEO & Chairman of Board Comp: $967.65kMr. Allan J. Lee Shaw CPA (Age 59)Chief Financial Officer Comp: $524.08kMr. Steven InnaimoVP of Project Management & OperationsDr. Robert A. Kramer Ph.D.Chief Scientific OfficerMr. Brian Wiley (Age 55)Chief Bus. Officer Comp: $220.69kMr. Justin FairchildVP of Devel.Mr. Joseph CiavarellaChief Accounting OfficerMore ExecutivesKey CompetitorsCelularityNASDAQ:CELURapid Micro BiosystemsNASDAQ:RPIDMarker TherapeuticsNASDAQ:MRKRLongeveronNASDAQ:LGVNImmunoPrecise AntibodiesNASDAQ:IPAView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 18,754 shares on 8/15/2023Ownership: 0.105%Bison Wealth LLCBought 213,398 shares on 8/14/2023Ownership: 1.199%Renaissance Technologies LLCBought 10,700 shares on 8/11/2023Ownership: 0.060%Ieq Capital LLCBought 16,650 shares on 8/8/2023Ownership: 0.094%Simplex Trading LLCSold 400 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions PRTG Stock - Frequently Asked Questions Should I buy or sell Portage Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTG shares. View PRTG analyst ratings or view top-rated stocks. What is Portage Biotech's stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price targets for Portage Biotech's stock. Their PRTG share price forecasts range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.67 in the next year. This suggests a possible upside of 396.7% from the stock's current price. View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts. How have PRTG shares performed in 2023? Portage Biotech's stock was trading at $5.2891 at the start of the year. Since then, PRTG stock has decreased by 51.8% and is now trading at $2.55. View the best growth stocks for 2023 here. Are investors shorting Portage Biotech? Portage Biotech saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,900 shares, a decline of 27.4% from the August 15th total of 9,500 shares. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company's stock are sold short. View Portage Biotech's Short Interest. When is Portage Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our PRTG earnings forecast. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) announced its earnings results on Wednesday, August, 30th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09. What is Portage Biotech's stock symbol? Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG." Who are Portage Biotech's major shareholders? Portage Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Bison Wealth LLC (1.20%), Citadel Advisors LLC (0.11%), Ieq Capital LLC (0.09%), Renaissance Technologies LLC (0.06%) and Simplex Trading LLC (0.00%). How do I buy shares of Portage Biotech? Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Portage Biotech's stock price today? One share of PRTG stock can currently be purchased for approximately $2.55. How much money does Portage Biotech make? Portage Biotech (NASDAQ:PRTG) has a market capitalization of $45.39 million. The company earns $-104,610,000.00 in net income (profit) each year or ($6.67) on an earnings per share basis. How can I contact Portage Biotech? Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806. This page (NASDAQ:PRTG) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.